Dupilumab Improves Dermatology-Specific Quality of Life in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1 Antihistamines

Chronic spontaneous urticaria (CSU) is characterized by wheals, angioedema, or both recurring for>6 weeks, affecting patients ’ quality of life (QoL). Here we report the effect of dupilumab on dermatology-specific QoL as measured by the Dermatology Life Quality Index (DLQI) in omalizumab-naïve CSU patients inadequately controlled with H1 antihistamines.

https://www.jacionline.org/article/S0091-6749(23)01524-5/abstract?rss=yes

Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Marcus Maurer, Thomas B. Casale, Lisa A. Beck, Sarbjit Saini, Moshe Ben-Shoshan, Gil Yosipovitch, J érôme Msihid, Philip Sugerman, Sonya Cyr, Ryan Thomas, Chien-Chia Chuang Source Type: research